ACR2008RA生物制剂与非生物制剂治疗.pdfVIP

目 录 Introduction 1 引言 2 Methods for Development of ACR RA 6 ACR类风湿关节炎治疗推荐的制定方法 7 ACR Recommendations for the Use of Nonbiologic and Biologic DMARDs in RA 12 美国风湿病学会（ACR）对治疗RA的DMARDs（包括非生物类和生物类）应用的推荐 13 Indications for starting or resuming a nonbiologic or biologic DMARD 12 非生物和生物DMARDs起始应用或重新应用的适应症 13 Contraindications to the use of nonbiologic and biologic DMARDs 20 非生物和生物DMARDs的禁忌症 21 Safety monitoring, risk surveillance, and preventive immunizations 24 安全性监测、风险监测和预防接种 25 TB screening for patients receiving biologic DMARDs 30 使用生物DMARDs治疗患者的TB筛查 31 Conclusion 31 结论 31 -1- Arthritis Rheumatism (Arthritis Care Research) Vol. 59, No. 6, June 15, 2008, pp 762–784 DOI 10.1002/art.23721 © 2008, American College of Rheumatology SPECIAL ARTICLE American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis KENNETH G. SAAG,1 GIM GEE TENG,1 NIVEDITA M. PATKAR,1 JEREMY ANUNTIYO,2 CATHERINE FINNEY,2 JEFFREY R. CURTIS,1 HAROLD E. PAULUS,2 AMY MUDANO,1 MARIA PISU,1 MARY ELKINS-MELTON,1 RYAN OUTMAN,1 JEROAN J. ALLISON,1 MARIA SUAREZ ALMAZOR,3 S. LOUIS BRIDGES, JR.,1 W. WINN CHATHAM,1 MARC HOCHBERG,4 CATHERINE MACLEAN,5 TED MIKULS,6 LARRY W. MORELAND,7 JAMES O’DELL,5 ANTHONY M. TURKIEWICZ,1 AND DANIEL E. FURST2 Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determination regarding their